Literature DB >> 23347056

Lowering of elevated tissue PCO2 in a hemorrhagic shock rat model after reinfusion of a novel nanobiotechnological polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase that is an oxygen and a carbon dioxide carrier with enhanced antioxidant properties.

Yuzhu Bian1, Gao Wei, Thomas M S Chang.   

Abstract

Even though erythrocytes transport both oxygen and carbon dioxide, research on blood substitutes has concentrated on the transport of oxygen and its vasoactivity and oxidative effects. Recent study in a hemorrhagic shock animal model shows that the degree of tissue PCO(2) elevation is directly related to mortality rates. We therefore prepared a novel nanobiotechnological carrier for both O(2) and CO(2) with enhanced antioxidant properties. This is based on the use of glutaraldehyde to crosslink stroma free hemoglobin (SFHb), superoxide dismutase (SOD), catalase (CAT) and carbonic anhydrase (CA) to form a soluble PolySFHb-SOD-CAT-CA. It was compared to blood and different resuscitation fluids on the ability to lower elevated tissue PCO(2) in a 2/3 blood volume loss rat hemorrhagic shock model. Sixty minutes of sustained hemorrhagic shock at 30 mm Hg resulted in the increase of tissue PCO(2) to 95 mm ± 3 mmHg from the control level of 55 mm Hg. Reinfusion of whole blood (Hb 15 g/dL with its RBC enzymes) lowered the tissue PCO2 to 72 ± 4.5 mmHg 60 minutes after reinfusion. PolySFHb-SOD-CAT-CA (SFHb 10 g/dL plus additional enzymes) was more effective than whole blood in lowering PCO(2) lowering this to 66.2 ± 3.5 mmHg. Ringer's Lactated solution or polyhemoglobin lowered the elevated PCO2 only slightly to 87 ± 4.5 mmHg and 84.8 ± 1.5 mmHg, respectively. Moreover, ST-elevation for whole blood (Hb 15 g/dL) and PolySFHb-SOD-CAT-CA (Hb 10 g/dL) was respectively 12.8% ± 4% and 13.0% ± 2% of the control 60 minutes after reinfusion. Both are significantly better than those in the Ringer's lactated group and the PolyHb group. In conclusion, this novel approach for blood substitute design has resulted in a novel nanobiotechnological carrier for both O(2) and CO(2) with enhanced antioxidant properties.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23347056      PMCID: PMC3618434          DOI: 10.3109/10731199.2013.745291

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  16 in total

1.  SEMIPERMEABLE MICROCAPSULES.

Authors:  T M CHANG
Journal:  Science       Date:  1964-10-23       Impact factor: 47.728

2.  Effects of polyhemoglobin-antioxidant enzyme complex on ischemia-reperfusion in kidney.

Authors:  E J Chang; T H Lee; K C Mun; H C Kim; S I Suh; J H Bae; S P Kim; K B Cho; J S Hwang
Journal:  Transplant Proc       Date:  2004-09       Impact factor: 1.066

Review 3.  Carbon dioxide transport and carbonic anhydrase in blood and muscle.

Authors:  C Geers; G Gros
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

4.  Stabilisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehyde.

Authors:  T M Chang
Journal:  Biochem Biophys Res Commun       Date:  1971-09-17       Impact factor: 3.575

5.  Cross-linked polyhemoglobin-superoxide dismutase-catalase supplies oxygen without causing blood-brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion.

Authors:  D Douglas Powanda; Thomas M S Chang
Journal:  Artif Cells Blood Substit Immobil Biotechnol       Date:  2002-01

6.  Skeletal muscle acidosis correlates with the severity of blood volume loss during shock and resuscitation.

Authors:  C Sims; P Seigne; M Menconi; J Monarca; C Barlow; J Pettit; J C Puyana
Journal:  J Trauma       Date:  2001-12

7.  Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial.

Authors:  Ernest E Moore; Frederick A Moore; Timothy C Fabian; Andrew C Bernard; Gerard J Fulda; David B Hoyt; Therese M Duane; Leonard J Weireter; Gerardo A Gomez; Mark D Cipolle; George H Rodman; Mark A Malangoni; George A Hides; Laurel A Omert; Steven A Gould
Journal:  J Am Coll Surg       Date:  2008-11-07       Impact factor: 6.113

8.  HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery.

Authors:  Jonathan S Jahr; Colin Mackenzie; L Bruce Pearce; Arkadiy Pitman; A Gerson Greenburg
Journal:  J Trauma       Date:  2008-06

9.  Detection of ischemia by PCO2 before adenosine triphosphate declines in skeletal muscle.

Authors:  Gunnvald Kvarstein; Peyman Mirtaheri; Tor Inge Tønnessen
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598

10.  Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties.

Authors:  F D'Agnillo; T M Chang
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

View more
  2 in total

1.  Novel Nanodimension artificial red blood cells that act as O2 and CO2 carrier with enhanced antioxidant activity: PLA-PEG nanoencapsulated PolySFHb-superoxide dismutase-catalase-carbonic anhydrase.

Authors:  Wei Gao; Yuzhu Bian; Thomas M S Chang
Journal:  Artif Cells Nanomed Biotechnol       Date:  2013-01-22       Impact factor: 5.678

2.  A novel nanobiotherapeutic poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the resuscitation of a rat model with 90 minutes of sustained severe hemorrhagic shock with loss of 2/3 blood volume.

Authors:  Yuzhu Bian; Thomas Ming Swi Chang
Journal:  Artif Cells Nanomed Biotechnol       Date:  2014-10-09       Impact factor: 5.678

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.